LONGITUDINAL EVALUATION OF SERUM ANDROGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE-CANCER

被引:91
|
作者
CARTER, HB
PEARSON, JD
METTER, EJ
CHAN, DW
ANDRES, R
FOZARD, JL
ROSNER, W
WALSH, PC
机构
[1] JOHNS HOPKINS UNIV HOSP, SCH MED, JAMES BUCHANAN BRADY UROL INST, DEPT LAB MED, BALTIMORE, MD 21287 USA
[2] NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA
[3] ROOSEVELT HOSP, DIV ENDOCRINOL, NEW YORK, NY USA
来源
PROSTATE | 1995年 / 27卷 / 01期
关键词
HORMONES; ANDROGENS; PROSTATE CANCER;
D O I
10.1002/pros.2990270106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age-matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6-9 over a period from 7-25 years prior to the diagnosis of prostate disease. There were no significant differences in age-adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0-5, 5-10, and 10-15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [1] ANDROGEN SUPPRESSION BY HYDROCORTISONE WITHOUT AMINOGLUTETHIMIDE IN ORCHIECTOMIZED MEN WITH PROSTATE-CANCER
    PERRY, LA
    PLOWMAN, PN
    ROWELL, NP
    CHARD, T
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (06): : 736 - 736
  • [2] PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN WITH AND WITHOUT PROSTATE-CANCER
    CHEN, IW
    KAPLAN, LA
    SPERLING, MI
    HEMINGER, LA
    MAXON, HR
    BRACKEN, RB
    JOURNAL OF UROLOGY, 1987, 137 (04): : A360 - A360
  • [3] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE
    CARTER, HB
    PEARSON, JD
    METTER, J
    BRANT, LJ
    CHAN, DW
    ANDRES, R
    FOZARD, JL
    WALSH, PC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16): : 2215 - 2220
  • [4] BODY DIMENSION DIFFERENCES IN MEN WITH OR WITHOUT PROSTATE-CANCER
    DEMARKWAHNEFRIED, W
    PAULSON, DF
    ROBERTSON, CN
    ANDERSON, EE
    CONAWAY, MR
    RIMER, BK
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (17) : 1363 - 1364
  • [5] ANDROGEN RECEPTORS IN PROSTATE-CANCER
    WHITE, RD
    OLSSON, CA
    UROLOGY, 1981, 17 (04) : 24 - 26
  • [6] PROSTATE-CANCER AND THE ANDROGEN RECEPTOR
    COETZEE, GA
    ROSS, RK
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 872 - 873
  • [7] PROSTATIC FLUID AND SERUM HORMONE LEVELS IN PROSTATE-CANCER
    ROSE, DP
    SOTARAUTA, M
    LAAKSO, K
    WYNDER, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 212 - 212
  • [8] EVALUATION OF CHANGES IN PSA IN THE MANAGEMENT OF MEN WITH PROSTATE-CANCER
    CARTER, HB
    PEARSON, JD
    SEMINARS IN ONCOLOGY, 1994, 21 (05) : 554 - 559
  • [9] ANDROGEN RECEPTOR ANALYSIS IN PROSTATE-CANCER
    MEYERS, FJ
    WHITE, RWD
    GUMERLOCK, PH
    CLINICAL RESEARCH, 1992, 40 (01): : A7 - A7
  • [10] ANDROGEN RECEPTOR AND FAMILIAL PROSTATE-CANCER
    SUN, S
    NAROD, SA
    APRIKIAN, A
    GHADIRIAN, P
    LABRIE, F
    NATURE MEDICINE, 1995, 1 (09) : 848 - 849